Telomir Pharmaceuticals Publishes Positive Preclinical Data for Telomir-Zn in Wilson's Disease

summarizeSummary

Telomir Pharmaceuticals announced the peer-reviewed publication of positive preclinical data for Telomir-Zn in a Wilson's disease model, demonstrating improved survival and reduced oxidative stress, which also supports its lead cancer program.

check_boxKey Events

• Peer-Reviewed Publication

  Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study on Telomir-Zn (Telomir-1) in the journal *Advances in Redox Research*.

• Positive Preclinical Results

  The study reported dose-dependent survival improvement, reductions in oxidative stress, decreased hepatic copper accumulation, improved liver injury biomarkers, and enhanced locomotor performance in a zebrafish model of Wilson's disease.

• Mechanistic Validation for Lead Program

  The findings support the mechanistic relevance of Telomir-Zn's approach for its lead program in Triple-Negative Breast Cancer, for which the company received FDA IND clearance in April 2026.

auto_awesomeAnalysis

This 8-K announces the peer-reviewed publication of preclinical data for Telomir-Zn (Telomir-1) in a Wilson's disease model. The study demonstrated dose-dependent survival improvement, reduced oxidative stress, and improved liver function, among other benefits. This scientific validation supports the drug's mechanism of action, which is also relevant to the company's lead program in Triple-Negative Breast Cancer, for which an IND was recently cleared. The positive preclinical results provide scientific backing for Telomir's pipeline as it navigates recent financial challenges and significant dilution.